Insta
Plasma Therapy May Be Removed As Covid-19 Treatment Option After Trials Reveal No Significant Benefit To Patients
ICMR Logo
The Government is looking to remove the convalescent plasma therapy from the national guidelines for the treatment of COVID-19 as the clinical trials conducted by the Indian Council of Medical Research (ICMR) have revealed that the therapy did not significantly benefit the patients, reports Livemint.
Sharing the development, ICMR's Director-General (DG) Dr Balram Bhargava said that the world's largest trial on plasma therapy has been conducted in India. The trial was conducted as a multi-centre study involving 464 patients.
He added, "We have had discussions at the National Task Force and we are discussing further with the joint monitoring group. This may be deleted from the national guidelines. That is the discussion ongoing and, more or less, we are reaching towards it."
The National Task Force, meanwhile, is also discussing whether remidesivir and hydroxychloroquine can also be removed from the clinical management guidelines, given a recently released pre-print of the World Health Organisation (WHO) Solidarity Trial showed that these did not help in the treatment of affected patients either. The WHO trial was an open-label trial involving 11,266 adults.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
